12 Jul 2012, BioSpectrum Bureau , BioSpectrum
New Delhi: Chennai-based bioinformatics and biomarker company Genome Life Sciences (GLS) recently received recognition for its in-house R&D facility from the Department Of Scientific and Industrial Research (DSIR) under the Ministry of Science and Technology, Goevrnment of India.
"We are pleased to receive DSIR recognition for our In-house R&D Unit," said Dr Narinder Singh , Head-Technology Innovation and Commercializing Research of Genome Life Sciences. "This recognition speaks of Genome Life Science's excellent track record of world-class research and technology development in the areas of next generation biomarker research using our patented technology, Functional Genomic fingerprinting, and in bioinformatics product development. This is a very significant milestone in our existence and officially approves that our infrastructure, man-power and scientific work is of world class standard and ready for national and international collaborations and commercializing the technologies in this business space," Dr Singh added.
"Bioinformatics and biomarker research is still in infancy stage in India. This recognition is a boost to Genome Life Science to promote further research in biomarker and bioinformatics and collaborate with other national and international institutions of excellence," he said.
Genome Life Science's R&D facility is to address the speedier development of next generation biomarkers using company's cutting edge functional genomic finger printing technology(FGF) from various sources and evolve clinically meaningful research outputs, diagnostic product development and plant molecular marker for rapid crop breeding programs.
The company is in advance stages of license agreement and knowledge-sharing tie-up with various MNCs in Pharma and agri-biotechnology companies, which will give them access to GLS's expertise and technology in biomarker research programs.
The R&D facility of the company has computer engineers, scientists and managers drawn from some of the world's best institutions across the world and has more than 6 patents world wide and 20 publication in international journals.
According to the DSIR website there are more than one thousand companies across all industries, including research labs set up by multinational companies which are recognized by DSIR in India. Within the pharma and biotech space, there are less than two hundred companies which got DSIR recognition .Genome Life Science is now a part of this selective group and one of the handful companies in bioinformatics and system biology space in India.
In-house R&D units recognized by DSIR in the area of biotechnology sector enables the company to enjoy a weighted tax deduction on its R &D expenses along with complete exemption of duties on import of materials , equipment and machinery for R&D purpose This recognition provides eligibility to obtain the financial assistance from various Govt. agencies.
GLS, a R&D operation of Genome International Corporation USA, a pioneer in next generation biomarker discovery and bioinformatics research. GLS was established in 2004 with the vision of developing innovative technology, Bioinformatics algorithms, tools, and databases for biomarker discovery in the areas of healthcare, veterinary, agriculture, food and related industries. The company provides life science databases of unique content developed with data mining algorithms along with their interactive and dynamic user interfaces. In addition, it provides data analysis products/services for the analysis of Next Generation Sequencing (NGS) data generated from all major platforms such as Illumina GA/HiSeq, ABI SOLiD, and Roche 454.
GLS is a provider of start-to-finish Next-Generation Sequencing and data analysis services, custom database development, contract research and bioinformatics consulting. GLS helps customers worldwide meet the bioinformatics challenges with its powerful tools and technologies.